Abivax S.A.
Business
Abivax S.A. is a clinical-stage biotechnology company developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in chronic inflammatory diseases. Its main product is obefazimod, an oral small-molecule miR-124 enhancer in clinical development for ulcerative colitis and Crohn’s disease, alongside follow-on miR-124–based compounds. The company’s activities center on clinical development programs, regulatory interactions, intellectual property and outsourced manufacturing and supply chain management. It conducts multinational clinical trials and development across North America, Latin America, Europe and Asia Pacific, relying on third-party CMOs and global regulatory channels.
Summary from filing dated 2025-03-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-336.10M |
| Total assets | $584.34M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |